Back to News
Market Impact: 0.15
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
Source: globenewswire.com
Healthcare & Biotech
Key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder, were presented at a scientific conference for the first time. The article excerpt provides no efficacy, safety, or other trial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Halozyme falls 6% as raised guidance fails to impress investors
- Dentsply earnings missed by $0.02, revenue fell short of estimates
- Cigna raises annual profit forecast on strength in health services unit
- US hospitals brace for tougher 2027 as coverage losses and Medicaid cuts loom
- Truist raises Zimmer Biomet stock price target on robotics progress